Abstract

EBT has undergone rigorous testing for reliability and validity of CAC measurements, and has been proven to be useful in identifying individuals with, or at risk for, coronary heart disease. Although MDCT is a promising tool for coronary calcium scoring, more studies are needed that compare EBT and MDCT scans in the same patients, especially with calcium scores of less than 100. Further radiation dose reduction strategies for MDCT are currently being evaluated. MDCT studies of progression, reproducibility, and outcomes are needed to fully evaluate its potential to measure and serially follow atherosclerosis compared to EBT. Studies examining the benefit of serial coronary calcium scoring to non-invasively assess the progression or regression of coronary calcium are currently underway. EBT is a method that can be used to estimate the overall coronary atherosclerotic plaque burden. It can be used to diagnose the presence and determine the extent of coronary atherosclerosis; furthermore, the calcium score information can be used to assess the likelihood of advanced obstructive disease and to provide prognostic information. Finally, serial CAC measurements by EBT have the potential to determine the efficacy of therapeutic interventions by demonstrating progression, stabilization, or regression of coronary atherosclerotic disease during therapy.